EP0510074A1 - Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen - Google Patents

Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Info

Publication number
EP0510074A1
EP0510074A1 EP91902981A EP91902981A EP0510074A1 EP 0510074 A1 EP0510074 A1 EP 0510074A1 EP 91902981 A EP91902981 A EP 91902981A EP 91902981 A EP91902981 A EP 91902981A EP 0510074 A1 EP0510074 A1 EP 0510074A1
Authority
EP
European Patent Office
Prior art keywords
radical
formula
porphyrin
derivative
indium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP91902981A
Other languages
English (en)
French (fr)
Inventor
Laurent Mauclaire
Catherine Bedel
Michel Pereyre
Jean-Claude Saccavini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CIS Bio International SA
Original Assignee
CIS Bio International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CIS Bio International SA filed Critical CIS Bio International SA
Publication of EP0510074A1 publication Critical patent/EP0510074A1/de
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B24GRINDING; POLISHING
    • B24BMACHINES, DEVICES, OR PROCESSES FOR GRINDING OR POLISHING; DRESSING OR CONDITIONING OF ABRADING SURFACES; FEEDING OF GRINDING, POLISHING, OR LAPPING AGENTS
    • B24B49/00Measuring or gauging equipment for controlling the feed movement of the grinding tool or work; Arrangements of indicating or measuring equipment, e.g. for indicating the start of the grinding operation
    • B24B49/003Measuring or gauging equipment for controlling the feed movement of the grinding tool or work; Arrangements of indicating or measuring equipment, e.g. for indicating the start of the grinding operation involving acoustic means
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Definitions

  • the metal to be included is yttrium, it is necessary to use higher temperatures, for example 250 ° C. for 4 hours.
  • Example 13 Preparation of the chloride of the 4-methylmercaptophenyl ester of (4- (carboxymethoxy) -phenyl) trimethylpyridylium porphyrin of indium (derivative no. 13).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Mechanical Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP91902981A 1990-01-10 1991-01-09 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen Ceased EP0510074A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9000214 1990-01-10
FR9000214A FR2656866B1 (fr) 1990-01-10 1990-01-10 Derives de porphyrine et metalloporphyrines eventuellement couples a une molecule biologiquement active, et composition pharmaceutique les contenant.

Publications (1)

Publication Number Publication Date
EP0510074A1 true EP0510074A1 (de) 1992-10-28

Family

ID=9392631

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91902981A Ceased EP0510074A1 (de) 1990-01-10 1991-01-09 Durch menschliche lymphozyten produzierte proteine, die für diese proteine kodierende dns und pharmazeutische und biologische verwendungen

Country Status (4)

Country Link
US (1) US5268371A (de)
EP (1) EP0510074A1 (de)
FR (1) FR2656866B1 (de)
WO (1) WO1991010667A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252730A (en) * 1992-04-10 1993-10-12 Northrop Corporation Polymer composition having intense magnetic properties and method for preparation thereof
US5464741A (en) * 1993-10-08 1995-11-07 Henwell, Inc. Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays
US6017496A (en) 1995-06-07 2000-01-25 Irori Matrices with memories and uses thereof
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US6331273B1 (en) 1995-04-25 2001-12-18 Discovery Partners International Remotely programmable matrices with memories
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US6416714B1 (en) 1995-04-25 2002-07-09 Discovery Partners International, Inc. Remotely programmable matrices with memories
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
WO2000000204A1 (en) 1997-02-14 2000-01-06 Miravant Pharmaceuticals, Inc. Indium photosensitizers for pdt
IL126953A0 (en) * 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
RU2157373C2 (ru) * 1998-12-29 2000-10-10 Институт химии нефти СО РАН Способ получения тетрафенилпорфина индия (iii) ацетата
AU6068200A (en) * 1999-07-01 2001-01-22 University Of Utah, The Nickel-based reagents for detecting dna and dna-protein contacts
US7371579B1 (en) 1999-07-01 2008-05-13 The University Of Maryland Nickel-based reagents for detecting DNA and DNA-protein contacts
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
JP2005524601A (ja) * 2000-09-15 2005-08-18 ザ スクリップス リサーチ インスティテュート 抗体による過酸化水素およびスーパーオキシド生成に関する方法および組成物
US6566517B2 (en) 2001-06-06 2003-05-20 Brookhaven Science Associates, Llc Metalloporphyrins and their uses as imageable tumor-targeting agents for radiation therapy
US7166478B2 (en) * 2002-03-12 2007-01-23 Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc. Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
GB2397067B (en) 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
US20050055487A1 (en) * 2003-09-04 2005-03-10 Toshiyuki Tanaka Rotating docking station
US6995260B2 (en) * 2004-05-20 2006-02-07 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US6989443B2 (en) * 2004-06-28 2006-01-24 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
EP2230242B1 (de) * 2009-03-16 2013-08-14 Johannes Kepler Universität Synthese von neuen asymmetrisch mesosubstituierten wasserlöslichen, als zytostatische Mittel wirkenden Porphyrinen
AU2017283653C1 (en) * 2016-06-16 2022-05-05 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
CN108752354A (zh) * 2018-06-11 2018-11-06 三峡大学 一种卟啉荧光染料的合成及其方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127797B1 (de) * 1983-06-03 1987-06-16 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Markermoleküle für Fluoreszenz-Immuno-Assays sowie Verfahren und Zwischenprodukte zu deren Herstellung
GB8429845D0 (en) * 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US4783529A (en) * 1985-12-03 1988-11-08 Research Corporation Technologies Rapid synthesis of radiolabeled porphyrin complexes for medical application
US4877872A (en) * 1986-06-24 1989-10-31 The University Of Toledo Production and use of dimers of hematoporophyrin, purpurins, chlorines and purpurin- and chlorin-complexes
US4851403A (en) * 1987-04-21 1989-07-25 Johnson Matthey, Inc. Radiation sensitizers
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
US5109016A (en) * 1988-05-23 1992-04-28 Georgia State University Foundation, Inc. Method for inhibiting infection or replication of human immunodeficiency virus with porphyrin and phthalocyanine antiviral compositions
FR2632187B1 (fr) * 1988-06-02 1990-09-14 Centre Nat Rech Scient Derives de metalloporphyrines, leur preparation, leur application en therapeutique et leur utilisation pour la preparation de molecules hybrides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9110667A1 *

Also Published As

Publication number Publication date
FR2656866A1 (fr) 1991-07-12
FR2656866B1 (fr) 1992-05-15
US5268371A (en) 1993-12-07
WO1991010667A1 (fr) 1991-07-25

Similar Documents

Publication Publication Date Title
WO1991010667A1 (fr) Derives de porphyrine et metalloporphyrines eventuellement couples a une molecule biologiquement active, et composition pharmaceutique les contenant
US5252317A (en) Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5135737A (en) Amplifier molecules for enhancement of diagnosis and therapy
DE3687399T2 (de) Porphyrinderivate, ihre herstellung und verwendung.
CA1339367C (en) Purified hematoporphyrin trimers useful in photodynamic therapy
EP0419387B1 (de) Hydrophile Derivate, diagnostische und therapeutische Anwendungen, diagnostische oder therapeutische Reagenziensätze und immunologische Reagenzien
FR2639947A1 (fr) Derives peptidiques
KR100358273B1 (ko) 광감작제
JPH0794392B2 (ja) 新規なテトラピロ−ルポリアミノモノカルボン酸医薬用組成物
JPS625985A (ja) 新規なテトラピロール化合物
EP0345171B1 (de) Metalloporphyrinderivate, ihre Herstellung, ihre therapeutische Anwendung und ihre Anwendung zur Herstellung von hybridischen Molekülen
DE69231952T2 (de) Komplexbildnermittel und zielimmunoreagenzien
PT93264B (pt) Processo para a preparacao de hidrazina bifuncional ou de derivados de hidrazina de conjugados que os contem e de macromoleculas marcadas com ioes metalicos
EP0350948A2 (de) Porphyrinderivate
EP0357622A1 (de) Substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
EP3004075A1 (de) Chelate von blei (ii) und wismut (iii) auf basis von trans-di-n-picolinat-tetraazacycloalkanen
JPH0615545B2 (ja) 金属フェオホーバイド誘導体および金属ポルフィリン誘導体
JPH07330773A (ja) ポルフィリン誘導体とその用途
CN1122132A (zh) 配位体及其金属配合物
JPH05501857A (ja) 感光性ディールス―アルダーポルフィリン誘導体
JP4866854B2 (ja) ホウ素化された金属フタロシアニン、その調製方法、これを有する医薬組成物及びその使用
USRE38994E1 (en) Pyropheophorbides conjugates and their use in photodynamic therapy
EP0595743B1 (de) Verbindungen mit zwei Haptenen zur Bindung von Technetium oder Rhenium, ihr Herstellungsverfahren, ihre Anwendung in Diagnostik und Therapie und sie enthaltende Reagenziensätze und immunologische Reagenzien.
JP2520735B2 (ja) ポルフィリン誘導体
WO2002040507A2 (fr) Nouveaux composes pour des applications a la radioimmunoscintigraphie et/ou a la radioimmunotherapie des cancers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI

17Q First examination report despatched

Effective date: 19930119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19940303

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE